Insulin resistance, the hallmark of non-insulin dependent diabetes mellitus, is characterized by the failure of tissues to take up and store glucose in response to insulin. Two recent studies shed new light on the importance of insulin signalling in the liver and how this may become defective in diabetes.
The predominant form of diabetes mellitus, non-insulin dependent diabetes mellitus (NIDDM) or type 2 diabetes, afflicts approximately 4% of the population of the Western world, and its treatment consumes more than 10% of the total National Health Service budget in Britain. The disease is characterised by the failure of sensitive tissues to respond normally to insulin -'insulin resistance'. These tissues therefore fail to take up and store glucose, leading to chronically elevated blood glucose ('hyperglycaemia'). In mild cases, increased insulin production by β cells in the pancreatic islets of Langerhans -leading to 'hyperinsulinaemia' -can compensate for the decreased responsiveness to the hormone, but diabetes results when the islets fail [1] . The causes of the disease remain poorly understood, but its predominance amongst overweight individuals -80% of type 2 diabetics are obese -suggests that dysregulated lipid metabolism may be an important factor.
The three major tissues largely responsible for clearing glucose from the blood in healthy individuals -liver, muscle and adipose tissue -all become insulin resistant in NIDDM, but the relative importance of each has been unclear. Two new studies [2, 3] shed light on this question. Michael et al. [2] have shown that targeted inactivation of the insulin receptor gene specifically in the liver leads to diabetes-like symptoms in mice. This is an important result, as it demonstrates that insulin has a direct role in regulating liver metabolism. Using two further animal models, Shimomura et al. [3] found that the development of insulin resistance in the liver involves selective inactivation of the capacity of insulin to block hepatic glucose production. On the other hand, the ability of the hormone to stimulate fatty acid synthesis is retained. So, as well as illuminating the importance of the liver as a target for insulin action, these studies also provide new information on the means by which the insulin receptor normally signals into cells.
Loss of the liver insulin receptor causes hyperglycaemia
Michael et al. [2] used a targeted approach to knockout the gene encoding that insulin receptor -a receptor tyrosine kinase -specifically in the liver. As previously described [4] , this technique involves breeding mice in which the wild-type insulin receptor gene has been replaced by one flanked with recombinase-sensitive lox sites, with animals expressing 'Cre' recombinase in a specific tissue, in this case hepatocytes. This results in a liver-specific insulin receptor gene knockout ('LIRKO') and severe insulin resistance in young (two month-old) animals. The resulting appearance of overt glucose intolerance is in contrast with the lack of effect of inactivating the insulin receptor gene in muscle ('MIRKO') [5] . The latter result was unexpected, given that skeletal muscle is responsible for >70% of glucose disposal following a carbohydrate meal [6] , with the liver accounting for most of the rest [7] .
Importantly, the new results clearly demonstrate that normal insulin signalling in the liver is important for dealing with a glucose load. This resolves a long-standing debate, as several groups (for example, [8] ) have previously proposed that elevated glucose production by the liver in starvation and diabetes may result only indirectly from the absence of insulin. The fact that injection of insulin failed to suppress glucose production by the liver in the LIRKO animals, whilst presumably suppressing lipolysis and the release of gluconeogenic precursors from muscle, indicates that the direct effects of insulin on this organ must be important in wild-type animals.
The LIRKO animals also show extraordinarily elevated (10-20-fold) levels of circulating insulin, as a result of the expansion of the islet β-cell mass (to approximately five times the normal level), hypersecretion of insulin and decreased hepatic insulin disposal [2] . This last result was expected, given that an active insulin receptor is necessary to permit hepatocytes to internalise and degrade the hormone. The mechanisms responsible for the spectacular islet hyperplasia, seen also in other rodent models of diabetes [9] , are unknown, but high blood glucose or insulin levels, or some liver-derived developmental factor, may be important. Interestingly, LIRKO animals do not suffer from a failure of insulin secretion even after a year of elevated insulin production -in humans, over-production of insulin is believed to cause 'β-cell exhaustion' and frank diabetes [10] (see below). It is uncertain, however, how closely the mouse LIRKO model mirrors the human condition where β-cell hyperplasia may be less pronounced and thus the strain on the pre-existing β-cell population correspondingly greater.
Selective changes in hepatic insulin receptor signalling
Whilst the LIRKO mice are a powerful new tool for investigating the importance of insulin signalling in the liver [2] , defects in the insulin receptor itself are not believed to play a significant role in most forms of NIDDM [11, 12] . Michael et al. [2] therefore used two models of insulin resistance, and examined hepatic gene expression to explore the lesion in hepatic insulin signalling. The first model is the well-known ob/ob mouse, which lack the satiety factor, leptin, encoded by the obese (ob) gene [13] . These animals over-eat, hypersecrete insulin and develop fatty livers. The second model was generated fortuitously when adipose tissue formation was suppressed -a condition called lypodystrophy -by expressing a dominant-negative form of the transcription factor known as either adipose differentiation/determining factor-1 (ADD1) or sterol response element binding protein-1 (SREBP1) [14] . In the absence of extrahepatic fat depots these mice, like the ob/ob animals, develop fatty livers and become severely insulin resistant.
In both models of insulin resistance, the inductive action of insulin on hepatic SREBP1 expression [15] is essentially unaffected. SREBP1 is therefore able to transactivate lipogenic genes, including those encoding glucokinase, acetyl CoA carboxylase and fatty acid synthase. By this means, hepatic lipid synthesis is expected to be enhanced. By contrast, the genes encoding gluconeogenic enzymes that are normally suppressed by insulin [16] , such as phophoenol pyruvate carboxykinase and glucose 6-phosphatase, are still expressed at high levels in the model mice.
Why should insulin be ineffective in regulating the gluconeogenic genes, whilst still able to induce the lipogenic genes? A likely explanation is that the levels of a key molecule in signalling from the insulin receptor -insulin receptor substrate-2 (IRS2) -were dramatically reduced in both models [3] . IRS2 and the other IRS isoforms [12] are normally phosphorylated by the insulin receptor tyrosine kinase when insulin is bound, leading to the recruitment of signalling molecules, notably phosphatidylinositol 3′-kinase. This in turn initiates protein kinase cascadesfor example, involving protein kinase B -leading ultimately to the transcriptional and metabolic effects of the hormone [12] . Consistent with these findings, IRS2 has been shown to be important in hepatic insulin receptor signalling [17] , whilst less important in muscle [18] . By contrast, the new data [3] show that the signalling pathway leading from the insulin receptor to SREBP1 is largely independent of IRS2.
Shimomura et al. [3] report evidence that the suppression of the IRS2 gene is likely to be the result hyperinsulinaemia. When they cultured isolated hepatocytes with elevated insulin concentrations, they found that IRS2 mRNA levels decreased, whilst destruction of β cells in vivo with streptozotocin caused an increase in the expression of IRS2 in the liver.
Future directions
These results leave a number of intriguing questions unanswered. Firstly, do persistently elevated insulin levels cause resistance in extrahepatic tissues, and can any such changes be explained by a drop in IRS2 expression? Examination of the level of expression of IRS2 in both the LIRKO and MIRKO mice [5] may shed light on this question; IRS2 levels are expected to be elevated in insulin receptor-deficient tissues but lower in other tissues [3] . Whether any change in IRS2 expression in muscle would further contribute to insulin resistance is, however, uncertain, given the greater importance of IRS1 in this tissue [18] .
Another question concerns the role of lipid accumulation in decreasing IRS2 levels in ob/ob and lipodystrophic mice livers [3] . Lipotoxicity is implicated in β-cell dysfunction [19] , and could result in part from SREBP1 overexpression Dispatch R737
Figure 1
A schematic illustration of the role of insulinaemia in the development of insulin resistance in the liver. Decreases in leptin (and elevated blood glucose) provoke enhanced insulin release from pancreatic islets, leading to a reduction in hepatic IRS2 levels, decreased activation of PKB, and a failure to suppress gluconeogenesis. At the same time, increases in SREBP1c activate lipogenic genes, prompting increased lipogenesis and the release of fatty acids. The latter, combined with glucose, cause further insulin release, setting up a 'vicious circle'. [20] (C. Zhao and G.A.R., unpublished data). In the pancreatic β cell, IRS2 appears to be particularly important in permitting feedforward effects of insulin [4, 21] , as attested by the insulin secretory defect in IRS2 -/-mice [22] . Suppression of IRS2 expression in the β cell following sustained hyperinsulinaemia might thus contribute to defective insulin production in the long term. Such an idea would represent an important paradigm shift as, up to now, β-cell failure has generally been attributed to hyperglycaemia ('glucose toxicity') [23, 24] .
Conclusions
Phosphorylation of IRS1 on serine (instead of tyrosine) residues has previously been implicated in insulin resistance caused by tumour necrosis factor α (TNFα) [25] . Taken with the new studies, this suggests that the IRS family may be frequent targets of agents which cause insulin resistance. These data also raise the question of whether IRS2 is an important new candidate gene/predictor for diabetes, though the answer from genetic screens seems likely to be 'no' [26] .
In the models described by Shimomura et al. [3] , glucose and fatty acid production by the liver are simultaneously enhanced ( Figure 1 ). This is likely to set up a feedforward, or vicious circle, leading to further insulin resistance, as circulating non-esterified fatty acids are likely to decrease the responsiveness to insulin of both liver and other tissues [27] . Furthermore, increased hepatic glucose production will enhance insulin release, causing the suppression of hepatic IRS2, and insulin-mediated inhibition of gluconeogenesis.
As pointed out by Shimomura et al. [3] , these results support the suggestion by McGarry [28] that diabetes should be considered not purely as a disease of glucose homeostasis but, at least equally, of defective lipid metabolism. A major issue will be to determine whether similar mechanisms for the development of hepatic insulin resistance, as delineated here in the rodent, pertain in humans.
